Covid-19 roundup: Re­gen­eron puts its an­ti­bod­ies in­to the clin­ic, rac­ing with Eli Lil­ly for fall au­tho­riza­tion

Re­gen­eron, ar­guably the most-watched de­vel­op­er of a Covid-19 an­ti­body treat­ment, is be­gin­ning clin­i­cal tri­als.

Like oth­er an­ti­body de­vel­op­ers, the big Tar­ry­town, NY biotech will be test­ing the drug both as a way of treat­ing Covid-19 pa­tients and pre­vent­ing peo­ple at high-risk from con­tract­ing the virus. They’ll con­duct four dif­fer­ent tri­als, be­gin­ning to­day with a tri­al for hos­pi­tal­ized pa­tients and a tri­al for non-hos­pi­tal­ized. Two pre­ven­ta­tive tri­als will come lat­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER